This message was sent to ##Email##
Regional 1 Registration Is Now Open!
Registration for the ASHI Regional Education Workshop 1 in Mesa, AZ from April 6-8, 2017, is now available! ASHI's Regional Education Workshops are designed to introduce emerging technologies and concepts that appeal to the newest members of the HLA community.
Register by March 7, 2017, to take advantage of our early registration rates.
Click here to register today!
Ends: Tuesday, March 7, 2017 11:59 p.m. EST
Starts: Wednesday, March 8, 2017 12 a.m. EST
|Member — Full Registration
|Member — Single Day
|Non-Member — Full Registration
|Non-Member — Single Day
Book Your Hotel Now!
Housing is now available for the Regional Education Workshop 1 in Mesa, AZ at the Sheraton Mesa Hotel at Wrigleyville West. Housing is available on a first-come, first-served basis. Book your housing today to guarantee your room!
Hotel Deadline: Tuesday, March 7, 2017
Room Rate: $159 Single/Double
Click here to reserve online or call 1-480-664-1221 and reference the ASHI Regional Education Workshop.
We are pleased to announce that the ASHI 2017 Regional Education Workshops Preliminary Program is available!
To review the program, click here!
*This program has been submitted to the American Board of Histocompatibility and Immunogenetics (ABHI). See upcoming announcements for final credit hours.
ASHI 2017 Regional Education Workshop Faculty
Amy Hahn, PhD, D(ABHI)
Karl Schillinger, MS, CHS(ABHI)
Jennifer Schiller, PhD, D(ABHI)
Nicole Valenzuela, PhD, D(ABHI)
Visit Our Website!
Save the Date!
ASHI Regional Education Workshop 2
June 8-10, 2017
The Hilton Providence
21 Atwells Avenue
Providence, RI 02903
Registration and Housing will open soon!
Information on registration rates, click here.
We hope that you'll take a few moments to renew your 2017 ASHI membership today to avoid disruption of your ASHI benefits.
Your membership dues allow us to provide programs, professional awards, and educational opportunities that advance the science, education and application of immunogenetics and transplant immunology.
|Abstract Submission Opens in February!
Abstract submission will be available soon! The deadline for abstract submission is Monday, April 10, 2017 at 11:59 p.m. Central Time. Stay tuned for more information regarding abstract submission.
44TH ANNUAL MEETING
October 1-5, 2018
Baltimore Marriott Waterfront
45TH ANNUAL MEETING
September 23-27, 2019
David L. Lawrence Convention Center
46TH ANNUAL MEETING
October 19-23, 2020
The next generation of Virtual Crossmatch is here!
VXmatch is a web and mobile-enabled application that displays all the crossmatch data you want; in exactly the way you want it. Want DSA trends, dilution, reactivity history, and graphs? VXmatch is a virtual crossmatch for labs who take it seriously.
The 2017 International Summer School will be held in Dublin, Ireland, July 24-26. Additional details will be provided as they become available.
|2017 International Summer School — Save the Date!
The membership has approved the recent bylaw amendment proposal! You no longer need to have sponsors in order to apply for ASHI membership!
Learn more about ASHI and HLA.
You must login to access the members only Forums.
If you would like to receive updates as content is posted, you must subscribe by clicking the Forum Actions Box at the top of the Forum page and subscribe to instant updates or/and click to subscribe to the Digest to get updates.
Click here for detailed instructions.
Why not join the conversation? Login here.
Current Forum topics being discussed include:
HLA Laboratory Business Model
It is my understanding there are two (2) types of business/financial models for HLA Laboratories:
1. Subsidiary of Hospital or University (Independent) OR
2. Hospital or University based
Would you be able to outline the guidelines of both types of labs and their business plan and financial map?
If anyone has experience in either type, can you please share any information and your experience.
DP Antibody in Heart, TX
I have a patient on our heart waiting list that was on ECMO and has an RVAD and LAVD implanted. He is very highly sensitized with a Bw4 antibody, additional B unacceptables, DR, DQ and DP antibodies. Our big concern is with his DP antibodies. He is DPB1*04:01 homozygous with antibodies >10,000 to almost all other DP antigens. We have done several surrogate crossmatches and they have all been B cell positive with anyone that is not 04:01 homozygous.
Does anyone have experience performing heart transplants across DP positive crossmatches? Did the patients have any issues post transplant? I know some have done kidney transplants with some success, but I have not seen any data about hearts.
I am interested in polling forum members to see how many labs use either EDTA treatment of serum or use a dilution (not endpoint titer) to address interferences such as prozoning for SAB testing. Please respond with any of the following:
I will share my findings when complete.
Contacting Patients for Serum Specimens
Our lab is getting pressure (led by the renal transplant coordinators) to be responsible for contacting patients who have not had their samples submitted for monthly antibody testing. I am curious whether some labs do this, rather than insisting that the coordinators, who already know the patients, be the contact persons. I feel that it is not the lab's responsibility.
What current challenges are you facing as a technologist?
How did you get started in HLA?
The acquired form of idiopathic thrombotic thrombocytopenic purpura (TTP) is an autoimmune disease, in which the underlying ADAMTS13-deficiency is caused by inhibitory autoantibodies against the protease. Human leukocyte antigens (HLA), responsible for antigen presentation, play an important role in the development of antibodies. The loci coding HLA DR and DQ molecules are inherited in linkage as haplotypes. The c.1858C>T polymorphism of the PTPN22 gene, which codes a protein tyrosine phosphatase important in lymphocyte activation, predisposes to a number of autoimmune diseases.
American Journal of Transplantation
De novo donor-specific antibody (dnDSA) is associated with antibody-mediated rejection (AMR) and allograft loss, yet the allograft histology associated with dnDSA remains unclear. The aim of this study was to examine the allograft histology associated with dnDSA in patients with serial surveillance biopsies. We retrospectively studied adult conventional solitary kidney transplant recipients from October 2007 to May 2014. The definition of dnDSA was new donor-specific antibody (DSA) with mean fluorescence intensity (MFI) >1000.
Immunotherapies have shown great promise in lung cancer patients, but only a small percentage actually responds to these treatments. Researchers have now shed some light onto why certain lung cancer patients fail to respond to immunotherapy Inactivating mutations in genes that code for the HLA-I (human leukocyte antigen-I) protein complex, which is required for immune recognition, impairs the recruitment and activation of immune cells within tumors, suggesting that this is likely a mechanism used by tumors to escape immune surveillance.
Potentially curative therapies for multiple myeloma (MM) based on various methods of adoptive immune cell transfer are advancing rapidly in clinical trials. The activity of these strategies in the clinical setting, although experimental, can no longer be considered hypothetical. At the 2016 annual meeting of the American Society of Hematology (ASH), responses reported in small trials were been dynamic and sustained, and the data promise a major evolution in standard MM treatment strategies.
|Click here to place your 2017 proficiency testing order, enter results or to view your laboratory’s previous performance reports and summary reports for surveys that have been completed.
|ASHI Career Center
Target your recruiting and reach qualified candidates quickly!
Looking for a new job or ready to take the next step? The ASHI Career Center will help you find the opportunity that's right for you!
|Access to educational information is free to ASHI members. CECs are awarded through an online testing process and are free to ASHI members.
7701 Las Colinas Ridge, Ste. 800, Irving, TX 75063